Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

References

• Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1):S2–25.
   PubMed Web of Science ®Google Scholar
• Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007;133:312–39.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van AG, Lindsay JO, Lemann M, Soderholm J, Colombel JF, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010;4:28–62.
   Google Scholar
• Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008;2:24–62.
   Google Scholar
• Allez M, Karmiris K, Louis E, Van AG, Ben-Horin S, Klein A, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn's Colitis 2010;4:355–66.
   Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685–98.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760–7.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011;34:1–10.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310–18.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;60:41–8.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51–8.
   PubMed Web of Science ®Google Scholar
• Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010;11:148–51.
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199–212.
   PubMed Web of Science ®Google Scholar
• Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment–shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857–69.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van AG, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492–500.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Maintenance of remission among patients With Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.
   PubMed Web of Science ®Google Scholar
• Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18:174–9.
   PubMed Web of Science ®Google Scholar
• Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010;32:1129–34.
   PubMed Web of Science ®Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944–8.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917–24.
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609–14.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3–11.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply. Aliment Pharmacol Ther 2011;34:404–5.
   Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430–8.
   PubMed Web of Science ®Google Scholar
• Domenech E, Hinojosa J, Nos P, Garcia-Planella E, Cabre E, Bernal I, Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107–13.
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Miheller P, Nyari T, Szepes Z, Herszenyi L, Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease? J Crohn's Colitis 2008;2:322–6.
   Google Scholar
• Laharie D, Mesli S, El HF, Chabrun E, Chanteloup E, Capdepont M, Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011;34:462–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–85.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Rizzi M, Monterubbianesi R, Marzo M, Cicala M, Guidi L, The course of infliximab discontinuation after long-term maintenance treatment in Crohn's disease. Gastroenterology 2010;138:S–687.
   Web of Science ®Google Scholar